STERIS plc (NYSE:STE) to Post Q3 2026 Earnings of $2.60 Per Share, Zacks Research Forecasts

STERIS plc (NYSE:STE) – Analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for STERIS in a research report issued to clients and investors on Tuesday, August 27th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.60 for the quarter, up from their previous forecast of $2.32. The consensus estimate for STERIS’s current full-year earnings is $9.17 per share. Zacks Research also issued estimates for STERIS’s Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.53 EPS.

STERIS (NYSE:STE) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the company posted $2.00 EPS. STERIS’s quarterly revenue was down .4% on a year-over-year basis.

Several other research firms have also issued reports on STE. JMP Securities reissued a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Piper Sandler reiterated a “neutral” rating and set a $225.00 price objective (up previously from $220.00) on shares of STERIS in a research note on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Finally, Stephens reiterated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.60.

STERIS Price Performance

Shares of STE stock opened at $241.10 on Friday. The firm has a fifty day moving average of $228.94 and a two-hundred day moving average of $224.50. The firm has a market cap of $23.78 billion, a P/E ratio of 63.12 and a beta of 0.83. STERIS has a 1-year low of $195.47 and a 1-year high of $243.37. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be paid a dividend of $0.57 per share. This is a boost from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, September 5th. This represents a $2.28 annualized dividend and a yield of 0.95%. STERIS’s dividend payout ratio (DPR) is presently 54.45%.

Insider Transactions at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now owns 582 shares in the company, valued at $139,493.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. First Personal Financial Services acquired a new position in shares of STERIS in the 1st quarter worth approximately $25,000. J.Safra Asset Management Corp lifted its position in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 53 shares during the last quarter. Quent Capital LLC lifted its position in shares of STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. VisionPoint Advisory Group LLC bought a new stake in shares of STERIS during the 4th quarter worth $34,000. Finally, Headlands Technologies LLC acquired a new position in shares of STERIS in the 1st quarter worth $36,000. 94.69% of the stock is owned by institutional investors and hedge funds.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.